James Frates Joins Amylyx Pharmaceuticals as Main Monetary Officer
3 min readCAMBRIDGE, Mass.–(Organization WIRE)–Jan 14, 2021–
Amylyx Pharmaceuticals, Inc., a pharmaceutical firm focused on producing new solutions for amyotrophic lateral sclerosis (ALS), Alzheimer’s Illness and other neurodegenerative conditions, today declared the appointment of James Frates as Main Economical Officer (CFO), powerful Jan. 25, 2021. Mr. Frates joins Amylyx next his tenure as CFO at Alkermes, since 1998.
This push release capabilities multimedia. See the whole launch below: https://www.businesswire.com/news/household/20210114005141/en/
James Frates, Amylyx Main Economic Officer (Image: Enterprise Wire)
“We are so thrilled for Jim to be a part of us at this significant juncture for Amylyx,” claimed Joshua Cohen, Co-CEO, Chairman and Co-Founder of Amylyx. “Jim’s depth and breadth of knowledge as a biopharmaceutical executive coupled with his money acumen and particular mission for bringing promising treatments to clients with ALS make him a superb addition to our leadership workforce.”
“Jim provides the one of a kind mixture of experience with developing biopharma organizations focused on the central anxious process, each as a CFO and a board member, and passion for the individuals we serve,” claimed Justin Klee, Co-CEO and Co-Founder of Amylyx. “Jim evidently embodies our values and we are thrilled to have him join our mission.”
Frates is an expert leader who served as Alkermes CFO via its expansion from a medical phase business to an intercontinental commercial and progress business with numerous goods, around $1 billion in revenue and about 2000 staff members. Frates aided deal with the enterprise as a result of quite a few acquisitions and financings in the credit card debt, fairness and personal marketplaces. Prior to Alkermes, Frates labored as an financial investment banker at Robertson, Stephens & Corporation and Morgan Stanley. Frates presently serves on the Board of Sage Therapeutics, Inc., The Roxbury Latin College and St. Francis Household in Boston. He is a graduate of Harvard University and attained an MBA from the Harvard Graduate University of Enterprise Administration.
“Since my cousin Pete Frates was diagnosed with ALS in 2012, and by his remarkable do the job with the Ice Bucket Challenge, I have felt a calling to become extra concerned in the fight to come across far more effective solutions. I am eager to join Amylyx because it has created so a lot development towards neurodegenerative conditions,” said Frates. “I believe that my encounter can assistance the organization scale and deliver on its assure of making a medicine that can assist hold off neurodegeneration in sufferers. The chance to support battle ALS signifies a fantastic deal to me and my household.”
About Amylyx Prescription drugs
Amylyx Prescription drugs, Inc. is a pharmaceutical organization performing on establishing a novel therapeutic for amyotrophic lateral sclerosis (ALS), Alzheimer’s disorder and other neurodegenerative disorders. For much more details, stop by www.amylyx.com and comply with us on LinkedIn and Twitter.
View resource edition on businesswire.com:https://www.businesswire.com/information/dwelling/20210114005141/en/
Make contact with: Merissa Muller
Finn Associates
(617) 778-6633
Key word: MASSACHUSETTS UNITED STATES NORTH The united states
Industry Key word: BIOTECHNOLOGY Psychological Wellness OTHER Wellness Health PHARMACEUTICAL
Supply: Amylyx Prescription drugs, Inc.
Copyright Company Wire 2021.
PUB: 01/14/2021 08:00 AM/DISC: 01/14/2021 08:01 AM
http://www.businesswire.com/news/residence/20210114005141/en
